From: Measurement of myocardial native T1 in cardiovascular diseases and norm in 1291 subjects
n | Age (years) | Male (n) | BMI (kg/m2) | HR (bpm) | LVEF (%) | LV mass index (g/m2) | LV Wallmin (mm) | LV Wallmax (mm) | |
---|---|---|---|---|---|---|---|---|---|
Patients with normal CMR | 70 | 48 ± 17 | 45 | 24 ± 3 | 65 ± 13 | 66 ± 9 | 56 ± 14 | 7 ± 1 | 10 ± 2 |
Cardiac Amyloidosis (AL) | 32 | 73 ± 11 | 11 | 28 ± 5 | 73 ± 13 | 55 ± 15a | 111 ± 32 | 12 ± 4 | 18 ± 3a |
Cardiac Amyloidosis (ATTR) | 22 | 75 ± 13 | 14 | 26 ± 4 | 79 ± 19 | 53 ± 14 | 120 ± 16 | 12 ± 3 | 20 ± 5 |
Anderson-Fabry diseaseb | 21 | 50 ± 17 | 20 | 27 ± 5 | 62 ± 14 | 60 ± 15 | 62 ± 25 | 8 ± 2 | 13 ± 5 |
Aortic Stenosis | 24 | 63 ± 18 | 19 | 29 ± 7 | 73 ± 13 | 62 ± 13 | 83 ± 23 | 9 ± 3 | 14 ± 3 |
Atrial Fibrillationb | 23 | 66 ± 11 | 18 | 28 ± 4 | 89 ± 19 | 50 ± 13a | 61 ± 13 | 7 ± 1 | 11 ± 2 |
Chronic CAD | 309 | 62 ± 12 | 193 | 28 ± 5 | 69 ± 14 | 50 ± 16a | 74 ± 23 | 7 ± 2 | 12 ± 3 |
Dilated Cardiomyopathy | 151 | 60 ± 15 | 98 | 27 ± 7 | 72 ± 15 | 35 ± 14a | 81 ± 29 | 5 ± 2a | 8 ± 2 |
Hypertrophic Cardiomyopathy | 185 | 56 ± 15 | 138 | 29 ± 11 | 68 ± 12 | 69 ± 12 | 88 ± 33 | 9 ± 3 | 19 ± 4a |
Hypertension | 59 | 62 ± 14 | 42 | 29 ± 5 | 68 ± 15 | 61 ± 16 | 83 ± 38 | 9 ± 2 | 14 ± 3 |
Cardiac Iron-Overloadb | 23 | 53 ± 21 | 17 | 23 ± 9 | 77 ± 14 | 65 ± 13 | 56 ± 27 | 7 ± 2 | 14 ± 3 |
Myocarditis (acute) | 146 | 41 ± 12a | 68 | 27 ± 5 | 75 ± 13 | 58 ± 13 | 69 ± 18 | 8 ± 2 | 12 ± 2 |
Myocarditis (previous) | 93 | 47 ± 17 | 72 | 27 ± 4 | 69 ± 14 | 61 ± 10 | 62 ± 17 | 7 ± 1 | 11 ± 2 |
Obesity | 38 | 53 ± 15 | 22 | 35 ± 4a | 70 ± 14 | 60 ± 10 | 60 ± 21 | 7 ± 1 | 10 ± 2 |
Pheochromocytoma | 29 | 50 ± 14 | 14 | 25 ± 6 | 71 ± 29 | 65 ± 10 | 57 ± 12 | 8 ± 1 | 10 ± 1 |
Cardiac Sarcoidosis | 21 | 59 ± 9 | 10 | 28 ± 6 | 74 ± 13 | 60 ± 14 | 64 ± 20 | 8 ± 2 | 13 ± 3 |
Takotsubo cardiomyopathy | 45 | 64 ± 12 | 35 | 25 ± 5 | 74 ± 18 | 60 ± 15 | 58 ± 17 | 8 ± 1 | 11 ± 3 |